PICO Portalanswers from OpenAlex & ORCID
Keith D. Wilner
ResearcherPublications, citations & collaboration network
Keith D. Wilner is a researcher indexed in PICO Portal from OpenAlex & ORCID.
How many works does Keith D. Wilner have?
PICO Portalindexed works
Keith D. Wilner has 240 works in the PICO Portal index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Keith D. Wilner have?
PICO Portalcitation count
Keith D. Wilner has 31,313 citations in the OpenAlex counts PICO Portal stores.
What is the h-index of Keith D. Wilner?
PICO Portalh-index
Keith D. Wilner has an h-index of 60 in OpenAlex.
What is the i10-index of Keith D. Wilner?
PICO Portali10-index
Keith D. Wilner has an i10-index of 129 in OpenAlex.
What is the ORCID of Keith D. Wilner?
PICO Portalorcid
The ORCID for Keith D. Wilner is on the source record.
What is the OpenAlex record for Keith D. Wilner?
PICO Portalopenalex
The OpenAlex for Keith D. Wilner is on the source record.
What are the most-cited papers on Keith D. Wilner?
PICO Portalmost cited works
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
Eunice L. Kwak, Yung‐Jue Bang, D. Ross Camidge, Alice T. Shaw, Benjamin Solomon, Robert G. Maki, Sai‐Hong Ignatius Ou, Bruce J. Dezube, Pasi A. Jänne, Daniel B. Costa, Marileila Varella‐Garcia, Woo Ho Kim, Thomas J. Lynch, Panos Fidias, Hannah Stubbs, Jeffrey A. Engelman, Lecia V. Sequist, Weiwei Tan, Leena Gandhi, Mari Mino–Kenudson, Greg C. G. Wei, S. Martin Shreeve, Mark J. Ratain, Jeffrey Settleman, James G. Christensen, Daniel A. Haber, Keith D. Wilner, Ravi Salgia, Geoffrey I. Shapiro, Jeffrey W. Clark, A. John Iafrate
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
Alice T. Shaw, Dong‐Wan Kim, Kazuhiko Nakagawa, Takashi Seto, Lucio Crinò, Myung‐Ju Ahn, Tommaso De Pas, Benjamin Besse, Benjamin Solomon, Fiona Blackhall, Yi‐Long Wu, Michael Thomas, Kenneth J. O’Byrne, Denis Moro‐Sibilot, D. Ross Camidge, Tony Mok, Vera Hirsh, Gregory J. Riely, Shrividya Iyer, Vanessa Tassell, Anna Polli, Keith D. Wilner, Pasi A. Jänne
First-Line Crizotinib versus Chemotherapy in <i>ALK</i>-Positive Lung Cancer
Benjamin Solomon, Tony Mok, Dong‐Wan Kim, Yi‐Long Wu, Kazuhiko Nakagawa, Tarek Mekhail, Enriqueta Felip, Federico Cappuzzo, Jolanda Paolini, Tiziana Usari, Shrividya Iyer, Arlene Reisman, Keith D. Wilner, Jennifer Tursi, Fiona Blackhall
Crizotinib in <i>ROS1</i>-Rearranged Non–Small-Cell Lung Cancer
Alice T. Shaw, Sai‐Hong Ignatius Ou, Yung‐Jue Bang, D. Ross Camidge, Benjamin Solomon, Ravi Salgia, Gregory J. Riely, Marileila Varella‐Garcia, Geoffrey I. Shapiro, Daniel B. Costa, Robert C. Doebele, Long P. Le, Zongli Zheng, Weiwei Tan, Patricia Stephenson, S. Martin Shreeve, L. Tye, James G. Christensen, Keith D. Wilner, Jeffrey W. Clark, A. John Iafrate
<i>ROS1</i> Rearrangements Define a Unique Molecular Class of Lung Cancers
Kristin Bergethon, Alice T. Shaw, Sai‐Hong Ignatius Ou, Ryohei Katayama, Christine M. Lovly, Nerina T. McDonald, Pierre P. Massion, Christina T. Siwak-Tapp, Adriana González, Rong Fang, Eugene J. Mark, Julie M. Batten, Haiquan Chen, Keith D. Wilner, Eunice L. Kwak, Jeffrey W. Clark, David P. Carbone, Hongbin Ji, Jeffrey A. Engelman, Mari Mino–Kenudson, William Pao, A. John Iafrate